Transimmunom is a Laboratory of Excellence project (LabEx) funded by the French government studying autoimmune and inflammatory diseases. The rational consists in a deep analysis of a set of pathologies with a collection of latest technologies. Results are integrated and analyzed all together to provide a better understanding of the underlying molecular processes involved in these pathologies. Therefore, this program is accelerating the discovery and the development of new therapies.
Transimmunom implies 6 clinical teams, 2 clinical laboratories, 5 academic research teams, 3 private companies and 6 patient’s organizations. This project is already beneficiating patients with the implementation of several clinical trials notably on type-2 diabetes and lupus. The large amount of data monitored on hundreds of patients is also beneficiating the scientific community and contribute to more than 20 publications since 2012.
The rationale for TRANSIMMUNOM stems from three main paradigms:
- Recent progresses in understanding inflammatory and autoimmune diseases.
This has led to realize that they form a continuum ranging from pure inflammatory diseases to pure autoimmune diseases. This encompasses a large panel of inflammatory diseases with some autoimmune component and autoimmune diseases with an inflammatory component. Thus, their cross-evaluation should translate in a better understanding of each disease pathophysiology.
- The immune system is a complex dynamic system made of a network of specialized cells and molecules.
Although the reductionist approach deployed to study it over the last 30 years has contributed major findings, there is a dimension of the immune response that can only be studied at more global, multilevel scales. Systems Biology offers the tools to perform such studies and will allow us to :
- improve our understanding of inflammatory and autoimmune diseases,
- identify novel genes/pathways,
- and to discover biomarkers and therapeutic targets.
- Inflammatory and autoimmune diseases are particularly suitable to the development of novel immunotherapies based on either drug, protein or cell intervention.
Of note, the monitoring of any intervention that modifies the immune response has a cognitive dimension.
The Transimmunom consortium comprises:
- Clinicians with strong research activities, with expertise covering immunopathology and inflammatory diseases, and with major records including pioneering clinical trials,
- Immunologists with expertise in state-of-the-art immune investigations and records in developing novel technologies,
- Scientists with expertise in computer science, bioinformatics, biostatistics, text-mining and data management,
- Three SMEs, ILTOO Pharma, Pharnext and Prediguard, involved in biomarker discovery and biotherapy development.
General Objective Is:
to study inflammation and immunopathologies by integrating basic, clinical and information sciences. We aim to break down some artificial boundaries by analyzing important phenotypes that cut across diagnostic groups and reconsider current disease classification schemes.
Specific Objectives Are:
- to cross-phenotype thirteen inflammatory and autoimmune diseases
- to discover and validate biomarkers and novel therapeutic targets to improve diagnosis and prognosis and treatment
- to improve and develop biotherapies based on this knowledge
For more information and the full project description please visit the project’s website at: https://transimmunom.fr